News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharm-Olam International Ltd. Adds Elite Talent to Optimize Clinical Operations


2/29/2012 9:28:26 AM

HOUSTON, TX, Feb. 29, 2012 – Pharm-Olam International Ltd. (POI) a multi-national full service CRO to pharmaceutical and biotech industries, is pleased to welcome John Barker as Executive Vice President, Corporate Operations. Within this post, Barker will be responsible for maintaining high-quality deliverables from POI's range of global trial services, including Government Contracts, Data Management, Biostatistics, and other functional services.

"It is a pleasure to welcome John Barker, an experienced leader to our executive team, whose core talents will benefit our entire organization," said John Hovre, Chief Operating Officer at POI. "Barker's extensive global CRO experience will contribute greatly to serve our sponsors with excellence, and maintain Pharm-Olam's continued global growth."

Barker comes to POI with extensive leadership and management experience within the global CRO industry. Prior to joining POI, Barker served in executive leadership roles including Senior Vice President of Global Government Clinical Trials at PPD, Vice President of Project Management at Quintiles, and Executive Vice President & General Manager of Clinical Operations at INC Research. Barker had direct responsibility for quality delivery on clinical trials, as well as managing global clinical operations and corporate project management system support. Additionally, he served as a Lieutenant Colonel in the U.S. Army.

For further information about conducting trials with Pharm-Olam please contact John Hovre, COO at john.hovre@pharm-olam.com.

About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES